GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President
Jun 17, 2021
LAS VEGAS - June 17, 2021 - (Newswire.com)
Dr. Andrea Small-Howard has been promoted to the role of President of GB Sciences, Inc. Dr. Small-Howard will also retain her roles as Chief Science Officer and member of the board of directors.
Joining GB Sciences in June of 2014 as the Chief Science Officer and a founding member of the board of directors, Dr. Small-Howard has made considerable contributions to the strategic vision and forward trajectory of the Company.
While performing the unique task of incubating a biotech company inside an operating cannabis company, Dr. Small-Howard co-invented a novel, AI-enabled drug discovery platform; created a novel drug development pipeline for plant-inspired, optimized therapeutic mixtures; and invented/co-invented 50+ patent applications for GB Sciences' growing intellectual property portfolio covering both GB Sciences' in silico drug discovery engine and their proprietary, plant-inspired drug formulations.
As President of GB Sciences, Inc., Dr. Small-Howard will mature the innovative programs that she has created over the past seven years. The Company's vision is to synergistically weave these separate programs into a highly innovative, plant-inspired biopharma company.
John Poss, CEO and Chairman of GB Sciences states, "Dr. Andrea Small-Howard has been and will be critical to the success of the Company going forward. She has been a joy to work with these past five years, and she has earned and very much deserves this role. Andrea possesses a rare combination of talents in innovative hard sciences and solid business practices. Great companies get great and stay great through continuity in their core team, and Andrea has largely been the architect and builder of our amazing science team. With a solid and positive five-year relationship under our belts, we are squarely focused on solid growth and achieving our goal of putting evidence-based medicine in the hands of patients."
"I am very grateful for this promotion, and I am more committed than ever to our goal of advancing our drug pipeline of novel, plant-inspired therapies for Parkinson's disease, chronic pain, cytokine release syndrome, heart failure, and others into human clinical trials. John and I have been resolute in this goal," said Dr. Small-Howard. "On the other hand, I am also very encouraged by the results being generated by PhAROS™, our novel drug discovery platform. It is a very exciting time to be at GB Sciences because we have the required tools that empower us to create new plant-inspired medicines to help our patients through regulated prescription drug pathways."
About GB Sciences
GB Sciences, Inc. (OTCQB: GBLX), through their Canadian entity, GBS Global Biopharma, Inc., is a phytomedicine research and biopharmaceutical drug development company whose goal is to create patented formulations of plant-inspired, optimized therapeutic mixtures (OTM) that target a variety of medical conditions. The active ingredients in our OTM are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices (cGMP). GB Sciences' novel drug discovery platform has yielded 5 issued US and 3 issued international patents, as well as 10 US and 35 international patent-pending applications. In our drug development pipeline, we have four preclinical stage programs, and our lead Parkinson's disease therapeutic program is being prepared for a First-in-Man clinical trial. In addition to Parkinson's disease, GB Sciences is developing therapeutics for neuropathic pain, cytokine release syndrome (CRS), Mast Cell Activation Syndrome (MCAS), and heart failure. GB Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. https://gbsciences.com
Media Contact
Alexis Quintal
[email protected]
Press Release Service by Newswire.com
Original Source: GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President
More News
Mortgage Rates Hover at 7.4%, Highest Since 2023
The average 30-year, fixed-rate mortgage has steadily risen in recent weeks, compounding affordability challenges for many Americans.
California’s Proposition 45 Brings the Sprawl Debate Back
Among the measures up for a vote in November is one that would amend the state’s landmark environmental law and make it easier to build large housing developments outside cities.
Nandy 'minded to intervene' in Sky's £1.6bn takeover of ITV entertainment arm
The culture secretary says the deal could affect free expression in the media and the variety of Britain's news landscape.
Midterms Could Shift Focus of Epstein Abuse to Banks’ Role
With an eye on retaking control of Congress, Democrats are introducing a bill that would hold banks accountable for their handling of Jeffrey Epstein’s finances.
What Is Starshield, SpaceX’s Military-Grade Satellite Internet Service Ukraine Relies On?
For years, Ukraine’s armed forces have relied on satellite communication services developed by Elon Musk’s SpaceX. Recent restrictions have hampered its war effort.
Energy Dept. Issues Emergency Order Amid Above-Average Temperatures
The order as a precaution allows grid operators to use backup generation this week. There were no widespread outages reported.
Healey says surprise UK growth is 'sign of resilience' ahead of Budget
The economy grew by 0.1% in August, defying analysts' expectations of a slight contraction.
Shook Research Changes Name to Veritant After Forbes Scandal
The company, known for its rankings of wealth advisers, sped up a rebranding after its founder acknowledged a secret $6 million payment to the top editor of Forbes.
The Fallout From the ‘Neocloud’ Wipeout
Investors are newly worried about the health of artificial intelligence infrastructure companies like CoreWeave. That’s weighing on the wider A.I. industry.
Tesla Debuts 2026 Roadster, an EV Sports Car at Least $200,000
Elon Musk’s company and other automakers, like Jaguar and Bentley, are trying to sell very expensive electric cars to people who usually prefer gasoline-fueled luxury and performance.
What Allegations of Spying at OpenAI Mean for the A.I. Industry
The arrest of an OpenAI employee accused of planting a bug in an office of the artificial intelligence giant flags another concern for the industry.
AI giant Anthropic woos potential investors ahead of stock market debut
It comes as some investors have become concerned about the amount of money being spent on AI infrastructure.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.